Sung Calvin T., Lee Alfred, Choi Franchesca, Juhasz Margit, Mesinkovska Natasha Atanaskova
J Drugs Dermatol. 2019 Jul 1;18(7):675-680.
Introduction: Injectable deoxycholic acid (DCA; Kybella; Allergan, Irvine, CA) is currently approved only for treatment of persistent submental fat (SMF). Many cosmetic surgeons use DCA off-label to treat fat tissue in other areas of the body. There is no review summarizing the off-label uses of injectable DCA. Methods: A systematic literature search was conducted through PubMed, Cochrane, CINAHL, and Web of Science databases using search terms “ATX-101 OR Kybella OR deoxycholic OR deoxycholate NOT amphotericin NOT bile” in accordance to PRISMA guidelines to identify off-label uses for injectable DCA or ATX-101. Results: Ten pertinent articles were identified for review. Anatomic areas treated include the face, brassiere line, foot, and gluteotrochanteric region. Indications include facial contouring, paradoxical adipose hyperplasia, HIV/HAART-associated buccal fat pad lipodystrophy, and reduction of lipomatous tumors. DCA is efficacious at causing lipolysis and safe with minimal side effects. Most patients treated for cosmetic indications reported high patient satisfaction. Conclusion: Off-label use of injectable DCA demonstrate a similar safety profile, effectiveness, and overall patient satisfaction compared to FDA-approved use for persistent SMF. DCA appears to be a safe and efficacious alternative to surgical reduction of unwanted adipose tissue in non-submental areas. Larger-scale studies are warranted to explore further cosmetic and potential medical applications. J Drugs Dermatol. 2019;18(7):675-680.
注射用脱氧胆酸（DCA；Kybella；艾尔建公司，加利福尼亚州欧文市）目前仅被批准用于治疗持续性颏下脂肪（SMF）。许多整形外科医生将DCA用于非标签适应证，以治疗身体其他部位的脂肪组织。目前尚无综述总结注射用DCA的非标签用途。方法：根据PRISMA指南，通过PubMed、Cochrane、CINAHL和Web of Science数据库进行系统文献检索，使用检索词“ATX-101或Kybella或脱氧胆酸或脱氧胆酸盐，不包括两性霉素，不包括胆汁”，以确定注射用DCA或ATX-101的非标签用途。结果：确定了10篇相关文章进行综述。治疗的解剖部位包括面部、胸罩线部位、足部和臀转子区。适应证包括面部轮廓塑形、反常性脂肪增生、HIV/高效抗逆转录病毒治疗相关的颊脂垫脂肪营养不良以及脂肪瘤的缩小。DCA在引起脂肪分解方面有效，且安全性高，副作用最小。大多数接受美容适应证治疗的患者报告患者满意度高。结论：与FDA批准用于持续性SMF的用途相比，注射用DCA的非标签使用显示出相似的安全性、有效性和总体患者满意度。DCA似乎是手术减少非颏下区域多余脂肪组织的一种安全有效的替代方法。有必要进行更大规模的研究，以探索进一步的美容和潜在医学应用。《药物皮肤学杂志》。2019年；18（7）：675-680。
